Key Material For Diagnostic Agent Temporarily Stops Exporting To Japan
This article was originally published in PharmAsia News
Due to a production halt caused by reactor trouble at Atomic Energy of Canada Ltd, molybdenum 99, a key material for cancer and vascular diagnostic agents, will not be exported to Japan temporarily. Japan Radioisotope Association May 26 notified medical facilities nationwide. The production halt is expected to last for more than one month. AECL accounts for over half of worldwide molybdenum 99 production. (Click here for more - Japanese language
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.